Status:
UNKNOWN
Efficacy and Safety of LongShengZhi Capsule on Functional Recovery After Acute Ischaemic Stroke (LONGAN)
Lead Sponsor:
Dongzhimen Hospital, Beijing
Conditions:
Ischemic Stroke
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of the study is to determine if LongShengZhi Capsule is effective and safe in patients with ischemic stroke in comparison to placebo. This trial is a prospective, multicenter, randomized, plac...
Eligibility Criteria
Inclusion
- Acute ischemic stroke patients within 7 days of onset
- 18 years of age or older, and gender not limited
- NIHSS score of 4 to 15
Exclusion
- Secondary stroke caused by a tumor, traumatic brain injury, hematological disease, or other diseases with a confirmed diagnosis
- Pre-stroke mRS score of more than 1
- Known severe liver or kidney dysfunction
- Known allergies for ingredients in the investigational product
- Known bleeding diathesis or coagulation disorder
- Known medical condition likely to limit survival to less than 3 months
- Pregnant women (clinically evident) or breastfeeding women
- Participation in any investigational study in the previous 3 months
- Known dementia, uncontrolled psychiatric problems
- Any condition that could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study. The judgment is left to the discretion of the investigator
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
1376 Patients enrolled
Trial Details
Trial ID
NCT05277311
Start Date
May 1 2022
End Date
June 30 2024
Last Update
March 14 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.